Inicio › Leucemia linfocítica crónica › Ohio
Ensayos clínicos de Leucemia linfocítica crónica en Ohio
44 estudios sobre Leucemia linfocítica crónica buscan participantes en Ohio.
Ciudades en Ohio
- Columbus29 estudios
- Cincinnati15 estudios
- Cleveland8 estudios
- Akron5 estudios
- Toledo3 estudios
- Dayton3 estudios
Texto oficial del estudio (inglés)
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 105, Canton
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT05645107Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04269902A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- University Hospitals, Cleveland
- Dayton Physician Network, Dayton
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06846671ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- OSU Comprehensive Cancer Center, Columbus
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07342478Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07734038HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
ReclutandoEstudio observacional
Edades de 12 a 80 · Todos los sexos · Actualizado el 6 nov 2026 · NCT07145411A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- The James Cancer Hospital and Solove Research Institute, Columbus
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT05091424A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Oncology Hematology Care Inc, Cincinnati
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07218341Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- y 44 más
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT05334069Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Cleveland Clinic Akron General, Akron
- OhioHealth O'Bleness Hospital, Athens
- Avon - Richard E Jacobs Health Center, Avon
- y 16 más
ReclutandoFase 3
Edades de 65 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07321652A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Cincinnati, Cincinnati
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07221500A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Columbus
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 oct 2026 · NCT06564038Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
ReclutandoFase 1/2
Edades de 13 a 90 · Todos los sexos · Actualizado el 26 oct 2026 · NCT06533579A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Oncology Hematology Care Clinical Trials, Llc, Cincinnati
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT06943872Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- The Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 oct 2026 · NCT06043674Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT07557056A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- University of Cincinnatti Medical Center, Cincinnati
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 oct 2026 · NCT06528301Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT07061951A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 104, Columbus
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07582432Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 75 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07685717A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Dayton Physician Network, Dayton
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06973187Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT07225439A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 31 jul 2026 · NCT06708897A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jul 2026 · NCT05131022A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 jun 2026 · NCT07271667Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 1
Edades de 2 en adelante · Todos los sexos · Actualizado el 29 may 2026 · NCT05418088Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
ReclutandoFase 1
Edades de 13 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT04771572The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
ReclutandoFase 1/2
Edades de 12 a 95 · Todos los sexos · Actualizado el 15 abr 2026 · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Cleveland Clinic Main Campus /ID# 271292, Cleveland
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 abr 2026 · NCT06428019A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 mar 2026 · NCT06876662Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 feb 2026 · NCT06466122Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 feb 2026 · NCT05336812Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05544019Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- The Ohio State University /ID# 230439, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 feb 2026 · NCT04895436Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 ene 2026 · NCT05417165Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
- University of Cincinnati, Cincinnati
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ene 2026 · NCT07014917Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
- University of Cincinnati, Cincinnati
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ene 2026 · NCT07108998Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 dic 2025 · NCT06757647De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.